Edition:
India

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

70.45USD
13 Jul 2018
Change (% chg)

$-0.07 (-0.10%)
Prev Close
$70.52
Open
$70.23
Day's High
$70.94
Day's Low
$70.23
Volume
171,103
Avg. Vol
334,787
52-wk High
$70.94
52-wk Low
$45.31

Select another date:

Fri, Apr 27 2018

BRIEF-Seattle Genetics Reports Q1 Loss Per Share Of $0.73

* SEATTLE GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Seattle Genetics Says CEO Clay Siegall's 2017 Total Compensation Was $8.6 Mln Vs $9.6 Mln In 2016‍​

* SEATTLE GENETICS INC SAYS CEO CLAY B. SIEGALL'S 2017 TOTAL COMPENSATION WAS $8.6 MLN VS $9.6 MLN IN 2016 – SEC FILING‍​‍​ Source text: (https://bit.ly/2GxkWMO) Further company coverage:

BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin

* SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval

U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years.

UPDATE 2-Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval

* Company expects $1 billion in Adcetris sales within few years

BRIEF-Seattle Genetics Announces FDA Approval Of Adcetris

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA

Seattle Genetics' Hodgkin's lymphoma drug gets U.S. approval

U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients.

BRIEF-Unum Therapeutics Sees IPO Of 5.8 Mln Shares Priced $12 - $14 Per Share

* UNUM THERAPEUTICS INC SEES IPO OF 5.8 MILLION SHARES OF COMMON STOCK PRICED TO BE BETWEEN $12.00 AND $14.00 PER SHARE - SEC FILING

BRIEF-Seattle Genetics Appoints Alpna Seth To Board

* SEATTLE GENETICS APPOINTS DR. ALPNA SETH TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

Select another date: